Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma

Cancer

Volumn 88, Issue 9, 2000, Pages 2033-2036

  Dinçol, Dilek ^a   Samur, Mustafa ^b   Pamir, Ali ^a   Şencan, Orhan ^a   Akbulut, Hakan ^a   Yalçin, Bülent ^a   Onur, Handan ^a   Demirkazik, Ahmet ^a   Śenler, Filiz Çay ^a   Içli, Fikri ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Chemotherapy; Chronotherapy; Granulocyte macrophage colony stimulating factor; Hematopoietic growth factors; Neutropenia

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; NEUTROPENIA; OSTEOSARCOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; THROMBOCYTE COUNT;

ADULT; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE NEOPLASMS; CHI-SQUARE DISTRIBUTION; CHRONOTHERAPY; FEMALE; FEVER; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; INJECTIONS, SUBCUTANEOUS; LEUKOCYTE COUNT; MALE; MONOCYTES; NEUTROPENIA; NEUTROPHILS; PLATELET COUNT; PROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS; TIME FACTORS;

EID: 0343619376     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000501)88:9<2033::AID-CNCR7>3.0.CO;2-R     Document Type: Article

References (9)

1. Vose JM, Armitage JO. Clinical applications of hematopoietic growth factors. J Clin Oncol 1995;13:1023-35.
2. Dinçol D, Akbulut H, Büyükçelik A, Içli F. Diurnal variations of serum G-CSF, GM-CSF and correlation with serum cortisol [Abstract 407]. Proc ASCO 1997;16:115a.
3. Rosenfeld CS, Sulecki M, Evans C, Shadduck RK. Comparison of intravenous versus subcutaneous recombinant granulocyte-macrophage colony stimulating factor in patients with primary myelodisplasia. Exp Hematol 1991;19:273-7.
4. Toner GC, Shapiro JD, Laidlaw CR, Rischin D, Millward MJ, Wolf M, et al. Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison. J Clin Oncol 1998;16:2874-9.
5. Crawford J, Kreisman H, Garewal H, Jones SE, Shoemaker D, Pupa MR, et al. The impact of filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Ann Oncol 1997;8:117-24.
6. Halberg F. Chronobiology. Ann Rev Physiol 1969;31:675-725.
7. Smaaland R, Laerum OD, Lote K, Sletvold O, Sothern RB, Bjerknes R. DNA synthesis in human bone marrow is circadian stage dependent. Blood 1991;77:2603-11.
8. Wood P, Hrushesky W, Klevecz R. Distinct circadian time structures characterize myeloid and erythroid progenitor and multipotential cell clonogenecity as well as marrow precursor proliferation dynamics. Exp Hematol 1998;26: 523-33.
9. Hrushesky WJM, Bjarnason GA. Circadian cancer therapy. J Clin Oncol 1993;11:1403-17.